Search Results for: ESR1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
SKP2 S-phase kinase associated protein 2
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • SCF(Skp2)-mediated degradation of p27/p21
  • Ub-specific processing proteases
  • Orc1 removal from chromatin
  • Cyclin D associated events in G1
  • Regulation of RUNX2 expression and activity
  • Neddylation
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
SLC30A9 solute carrier family 30 member 9
SMAD2 SMAD family member 2
  • Signaling by NODAL
  • Signaling by NODAL
  • Signaling by Activin
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • SMAD4 MH2 Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Transcriptional regulation of pluripotent stem cells
  • Ub-specific processing proteases
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
  • Dexfosfoserine
  • Colorectal cancer
SMAD3 SMAD family member 3
  • Signaling by NODAL
  • Signaling by NODAL
  • Signaling by Activin
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • SMAD4 MH2 Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Ub-specific processing proteases
  • RUNX3 regulates CDKN1A transcription
  • RUNX3 regulates BCL2L11 (BIM) transcription
  • Interleukin-37 signaling
  • NOTCH4 Intracellular Domain Regulates Transcription
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
SMAD4 SMAD family member 4
  • Signaling by NODAL
  • Signaling by Activin
  • Signaling by BMP
  • TGF-beta receptor signaling activates SMADs
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • SMAD4 MH2 Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Transcriptional regulation of pluripotent stem cells
  • Ub-specific processing proteases
  • RUNX2 regulates bone development
  • RUNX3 regulates CDKN1A transcription
  • RUNX3 regulates BCL2L11 (BIM) transcription
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
  • Colorectal cancer
  • Hereditary hemorrhagic telangiectasia (HHT)
  • Pancreatic cancer
  • Juvenile polyposis syndrome
SMARCA2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2
  • RMTs methylate histone arginines
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
  • Interleukin-7 signaling
  • Formation of the beta-catenin:TCF transactivating complex
  • RMTs methylate histone arginines
  • Chromatin modifying enzymes
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • EGR2 and SOX10-mediated initiation of Schwann cell myelination
  • EGR2 and SOX10-mediated initiation of Schwann cell myelination
SMARCD1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1
  • RMTs methylate histone arginines
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
SMARCD3 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3
  • RORA activates gene expression
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • RMTs methylate histone arginines
  • Transcriptional regulation of white adipocyte differentiation
  • Regulation of lipid metabolism by PPARalpha
  • Circadian Clock
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
SMARCE1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1
  • RMTs methylate histone arginines
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • Phenethyl Isothiocyanate
SMC1A structural maintenance of chromosomes 1A
  • Meiotic synapsis
  • Separation of Sister Chromatids
  • Establishment of Sister Chromatid Cohesion
  • Cohesin Loading onto Chromatin
  • Resolution of Sister Chromatid Cohesion
  • SUMOylation of DNA damage response and repair proteins
  • Estrogen-dependent gene expression
  • Cornelia de Lange syndrome (CdLS)
SMC3 structural maintenance of chromosomes 3
  • Meiotic synapsis
  • Separation of Sister Chromatids
  • Establishment of Sister Chromatid Cohesion
  • Cohesin Loading onto Chromatin
  • Resolution of Sister Chromatid Cohesion
  • SUMOylation of DNA damage response and repair proteins
  • Estrogen-dependent gene expression
  • Cornelia de Lange syndrome (CdLS)
SMYD2 SET and MYND domain containing 2
  • PKMTs methylate histone lysines
  • Regulation of TP53 Activity through Methylation
SND1 staphylococcal nuclease and tudor domain containing 1
  • Signaling by BRAF and RAF fusions
SNX6 sorting nexin 6
SOS1 SOS Ras/Rac guanine nucleotide exchange factor 1
  • SOS-mediated signalling
  • SOS-mediated signalling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Signalling to RAS
  • Signalling to RAS
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • NRAGE signals death through JNK
  • Rho GTPase cycle
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • SHC-related events triggered by IGF1R
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • NCAM signaling for neurite out-growth
  • G alpha (12/13) signalling events
  • Activation of RAC1
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Insulin receptor signalling cascade
  • MET activates RAS signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Interleukin-15 signaling
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • Interleukin receptor SHC signaling
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
SP1 Sp1 transcription factor
  • PPARA activates gene expression
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Activation of gene expression by SREBF (SREBP)
  • Oncogene Induced Senescence
  • RNA polymerase II transcribes snRNA genes
  • RNA polymerase II transcribes snRNA genes
  • Estrogen-dependent gene expression
SP3 Sp3 transcription factor
  • SUMOylation of transcription factors
SRA1 steroid receptor RNA activator 1
SRC SRC proto-oncogene, non-receptor tyrosine kinase
  • Signaling by ERBB2
  • Nuclear signaling by ERBB4
  • Downregulation of ERBB4 signaling
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • Downstream signal transduction
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • G alpha (s) signalling events
  • G alpha (i) signalling events
  • G alpha (i) signalling events
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • RAF activation
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PTK2 signaling
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of RUNX1 Expression and Activity
  • RUNX2 regulates osteoblast differentiation
  • Regulation of RUNX3 expression and activity
  • Extra-nuclear estrogen signaling
  • Activated NTRK2 signals through FYN
  • Activated NTRK3 signals through PI3K
  • Activated NTRK3 signals through PI3K
  • Long-term potentiation
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric acid
  • Paratoulene phosphate
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • XL228
  • Tirbanibulin
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • PD-168393
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • PP-121
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
  • Nintedanib
  • Fostamatinib

Page 16 out of 19 pages